Barcelona snapshots

Prof. Herbert Y. Meltzer

Herbert Y. Meltzer psiquiatra Controversias Psiquiatría Barcelona
Northwestern University, EE.UU.
Ponencia La neurobiología de la resistencia al tratamiento: más allá de la dopamina y la psicosis persistente
Fecha Viernes, 26 de Abril, 2019
Hora 11:00 a 11:45
Mesa redonda Resistencia al tratamiento en esquizofrenia

BIOGRAFÍA

Herbert Y Meltzer, MD, is Professor of Psychiatry and Behavioral Sciences and Professor of Pharmacology and Physiology at the Northwestern University Feinberg School of Medicine, Chicago, Il He has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). He has published >950 peer reviewed publications and 150 book chapters, relating to schizophrenia, mood disorders and suicide, addressing both clinical and basic neuroscience aspects (Hirsch Index 116). His research emphasizes translational neuropsychopharmacoloty. Dr Meltzer led the research for approval of clozapine for treatment resistant schizophrenia and suicide ,and the use of atypical antipsychotic drugs to treat the cognitive impairment of schizophrenia. More recently, he led the development of the first non-dopamine antagonist-based antipsychotic drug, pimavanserin, a selective 5-HT2A antagonist, now approved for treatment of Parkinson’s psychosis.

Dr. Meltzer is the recipient of the Research Prize of the American Psychiatric Association (2005), the Lifetime Achievement Award of the Schizophrenia International Research Society(2016), the Pioneer Award of the International College of Neuropsychopharmacology (2016) and numerous other awards.

Current research interests include: 1) the discovery and elucidation of the mechanism of action of novel pharmacologic treatments for schizophrenia and related psychiatric disorders, neurodegenerative diseases, and aging, as well as rapidly acting antidepressants and anti-suicide drugs (e.g. rapastinel); 2) pharmacogenetic tests to predict response to antipsychotic drugs; and 3 animal models of components of the psychotic spectrum disorders.

RESUMEN

REFERENCIAS